Genmab A (GMAB) Total Non-Current Liabilities (2023 - 2025)
Genmab A (GMAB) has disclosed Total Non-Current Liabilities for 3 consecutive years, with $5.6 billion as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Total Non-Current Liabilities rose 950.47% year-over-year to $5.6 billion, compared with a TTM value of $5.6 billion through Dec 2025, up 950.47%, and an annual FY2025 reading of $5.6 billion, up 950.47% over the prior year.
- Total Non-Current Liabilities was $5.6 billion for Q4 2025 at Genmab A, up from $533.0 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $5.6 billion in Q4 2025 and bottomed at $177.0 million in Q4 2023.
- Average Total Non-Current Liabilities over 3 years is $2.1 billion, with a median of $533.0 million recorded in 2024.
- The sharpest move saw Total Non-Current Liabilities skyrocketed 201.13% in 2024, then skyrocketed 950.47% in 2025.
- Year by year, Total Non-Current Liabilities stood at $177.0 million in 2023, then surged by 201.13% to $533.0 million in 2024, then surged by 950.47% to $5.6 billion in 2025.
- Business Quant data shows Total Non-Current Liabilities for GMAB at $5.6 billion in Q4 2025, $533.0 million in Q4 2024, and $177.0 million in Q4 2023.